Skip to main content

Advertisement

SpringerLink
Log in

A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours

  • Diagnostic Neuroradiology
  • Published:
Neuroradiology Aims and scope Submit manuscript

Abstract

A two-centre intra-individual crossover study was performed in 23 patients with suspected high-grade glioma or metastases to assess and compare the safety and enhancement characteristics of two different MRI contrast media (gadobenate dimeglumine, Gd-BOPTA and gadoterate meglumine, Gd-DOTA) at equivalent doses of 0.1 mmol/kg body weight. T1-weighted spin-echo (SE) and T2-weighted fast SE images were obtained before and T1-weighted images 0, 2, 4, 6, 8 and 15 min after injection. T1-weighted images with magnetisation transfer contrast were acquired 12 min after injection. Qualitative assessment by blinded, off-site readers (reader 1: 19 patients; reader 2: 21) and on-site investigators (23) revealed significant (P ≤0.005) overall preference for Gd-BOPTA over Gd-DOTA for contrast enhancement (Gd-BOPTA preferred in 18, 15 and 18 cases; Gd-DOTA in 0, 1 and 1 and no preference in 1, 5 and 4; off-site readers 1 and 2, and on-site investigators, respectively). A similar significant preference for Gd-BOPTA was expressed by off-site readers and on-site investigators for lesion-to-brain contrast, lesion delineation, internal lesion structure, and overall image preference. Quantitative assessment by off-site readers revealed significantly (p<0.05) greater lesion enhancement with Gd-BOPTA than with Gd-DOTA at all times from 2 min after injection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Healy ME, Hesselink JR, Press GA, Middleton MS (1987) Increased detection of intracranial metastases with intravenous Gd-DTPA. Radiology 165: 619–624

    CAS  PubMed  Google Scholar 

  2. Byrne TN (1994) Imaging of gliomas. Semin Oncol 21: 162–171

    CAS  PubMed  Google Scholar 

  3. Runge VM, Muroff LR, Wells JW (1997) Principles of contrast enhancement in the evaluation of brain diseases: an overview. J Magn Reson Imaging 7: 5–13

    CAS  PubMed  Google Scholar 

  4. de Haën C, Cabrini M, Akhnana L, Ratti D, Calabi L, Gozzini L (1999) Gadobenate dimeglumine 0.5 M solution for injection (MultiHance®): pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr 23 [Suppl. 1]: S161–S168

  5. Yuh WTC, Fisher DJ, Engelken JD, et al (1991) MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology 180: 485–491

    CAS  PubMed  Google Scholar 

  6. Myhr G, Rinck PA, Børseth A (1992) Gadodiamide injection and gadopentetate dimeglumine. A double-blind study in MR imaging of the CNS. Acta Radiol 33: 405–409

    CAS  PubMed  Google Scholar 

  7. Balériaux D, Matos C, De Greef D (1993) Gadodiamide injection as a contrast medium for MRI of the central nervous system: a comparison with gadolinium-DOTA. Neuroradiology 35: 490–494

    PubMed  Google Scholar 

  8. Valk J, Algra PR, Hazenberg CJ, Slooff WBM, Slavand MG (1993) A double-blind, comparative study of gadodiamide injection and gadopentetate dimeglumine in MRI of the central nervous system. Neuroradiology 35: 173–177

    CAS  PubMed  Google Scholar 

  9. Brugières P, Gaston A, Degryse HR, et al (1994) Randomised double blind trial of the safety and efficacy of two gadolinium complexes (Gd-DTPA and Gd-DOTA). Neuroradiology 36: 27–30

    PubMed  Google Scholar 

  10. Åkeson P, Jonsson E, Haugen I, Holtas S (1995) Contrast-enhanced MRI of the central nervous system: comparison between gadodiamide injection and gadolinium-DTPA. Neuroradiology 37: 229–233

    Article  PubMed  Google Scholar 

  11. Oudkerk M, Sijens PE, van Beek EJ, Kuijpers TJ (1995) Safety and efficacy of Dotarem (Gd-DOTA) versus Magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Invest Radiol 30: 75–78

    CAS  PubMed  Google Scholar 

  12. Grossman RI, Rubin DI, Hunter G, et al (2000) Magnetic resonance imaging in patients with central nervous system pathology. A comparison of OptiMARK (Gd-DTPA-BMEA) and Magnevist (Gd-DTPA). Invest Radiol 35: 412–419

    Article  CAS  PubMed  Google Scholar 

  13. Greco A, Parker JR, Ratcliffe CG, Kirchin MA, McNamara MT (2001) Phase III, randomized, double blind, crossover comparison of gadoteridol and gadopentetate dimeglumine in magnetic resonance imaging of patients with intracranial lesions. Australas Radiol 45: 457–463

    Article  CAS  PubMed  Google Scholar 

  14. Runge VM, Kirsch JE, Burke VJ, et al (1992) High dose gadoteridol in MR imaging of intracranial neoplasms. J Magn Reson Imaging 2: 9–18

    CAS  PubMed  Google Scholar 

  15. Yuh WTC, Engelken JD, Muhonen MG, Fisher DJ, Erhardt JC (1992) Experience with high dose gadolinium MR imaging in the evaluation of brain metastases. AJNR 13: 335–345

    CAS  PubMed  Google Scholar 

  16. Haustein J, Laniado M, Niendorf H-P, et al (1993) Triple dose versus standard-dose gadopentetate dimeglumine: a randomized study in 199 patients. Radiology 186: 855–860

    CAS  PubMed  Google Scholar 

  17. Yuh WTC, Halloran JI, Mayr NA, Fisher DJ, Nguyen HD, Simonson TM (1994) Dose of contrast material in the MR imaging evaluation of central nervous system tumors. J Magn Reson Imaging 4: 242–249

    Google Scholar 

  18. Yuh WTC, Fisher DJ, Runge VM, et al (1994) Phase III multicenter trial of high dose gadoteridol in MR evaluation of brain metastases. AJNR 15: 1037–1051

    CAS  PubMed  Google Scholar 

  19. Yuh WTC, Tali ET, Nguyen HD, Simonson TM, Mayr NA, Fisher DJ (1995) The effect of contrast dose, imaging time and lesion size in the MR detection of intracerebral metastasis. AJNR 16: 373–380

    CAS  PubMed  Google Scholar 

  20. Van Dijk P, Sijens PE, Schmitz PI, Oudkerk M (1997) Gd-enhanced MR imaging of brain metastases: contrast as a function of dose and lesion size. Magn Reson Imaging 15: 535–541

    PubMed  Google Scholar 

  21. Sze G, Johnson C, Kawamura Y, et al (1998) Comparison of single- and triple-dose contrast material in the MR screening of brain metastases. AJNR 19: 821–828

    CAS  PubMed  Google Scholar 

  22. Yuh WTC, Maley JE (1998) Contrast dosage in the neuroimaging of brain tumors. Magn Reson Imaging Clin North Am 6: 113–124

    Google Scholar 

  23. Anon. ProHance® (gadoteridol injection) package insert. Bracco Diagnostics, Princeton

  24. Anon. Omniscan® (gadodiamide injection) package insert. Nycomed-Amersham, Princeton

  25. Cavagna FM, Maggioni F, Castelli PM, et al (1997) Gadolinium chelates with weak binding to serum proteins. Invest Radiol 32: 780–796

    CAS  PubMed  Google Scholar 

  26. Colosimo C, Ruscalleda J, Korves M, et al (2001) Detection of intracranial metastases: a multi-center, intra-patient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dose. Invest Radiol 36: 72–81

    CAS  PubMed  Google Scholar 

  27. Runge VM, Armstrong MR, Barr RG, et al (2001) A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology. Invest Radiol 36: 65–71

    CAS  PubMed  Google Scholar 

  28. Runge VM, Parker JR, Donovan M (2002) Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain. Invest Radiol 37: 269–280

    Article  PubMed  Google Scholar 

  29. Schneider G, Kirchin MA, Pirovano G, et al (2001) Gadobenate dimeglumine-enhanced magnetic resonance imaging of intracranial metastases: effect of dose on lesion detection and delineation. J Magn Reson Imaging 14: 525–539

    Article  CAS  PubMed  Google Scholar 

  30. Balériaux D, Colosimo C, Ruscalleda J, et al (2002) Magnetic resonance imaging of metastatic disease to the brain with gadobenate dimeglumine. Neuroradiology 44: 191–203

    Article  PubMed  Google Scholar 

  31. Cohen J (1960) A coefficient of agreement for nominal scales. Educ Psychol Measurement 20: 37–46

    Google Scholar 

  32. Koch GG (1972) The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics 28: 577–584

    CAS  PubMed  Google Scholar 

  33. Parizel PM, Degryse HR, Gheuens J, et al (1989) Gadolinium-DOTA enhanced MR imaging of intracranial lesions. J Comput Assist Tomogr 13: 378–385

    Google Scholar 

  34. Knopp MV, Runge VM, Essig M, et al (2004) Primary and secondary brain tumors: a bicentric intra-individual crossover comparison of gadobenate dimeglumine with gadopentetate dimeglumine for lesion enhancement. Radiology 230: 55–64

    PubMed  Google Scholar 

  35. Knopp MV, Schoenberg SO, Rehm C, et al (2002) Assessment of gadobenate dimeglumine (Gd-BOPTA) for MR angiography: phase I studies. Invest Radiol 37: 706–715

    Article  CAS  PubMed  Google Scholar 

  36. Völk M, Strotzer M, Lenhart M, et al (2001) Renal time-resolved MR angiography: quantitative comparison of gadobenate dimeglumine and gadopentetate dimeglumine with different doses. Radiology 220: 484–488

    PubMed  Google Scholar 

  37. Schneider G, Maas R, Schultze Kool L, et al (2003) Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Invest Radiol 38: 85–94

    Article  CAS  PubMed  Google Scholar 

  38. Seitz RJ, Wechsler W (1987) Immunohistochemical demonstration of serum proteins in human cerebral gliomas. Acta Neuropathol (Berl) 73: 145–152

    Google Scholar 

  39. Finelli DA, Hurst GC, Gullapali RP, Bellon EM (1994) Improved contrast of enhancing brain lesions on post-gadolinium, T1-weighted spin-echo images with use of magnetization transfer. Radiology 190: 553–559

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Radiology, Department of Clinical Sciences and Bioimaging, University G. d’Annunzio, via Colle dell’Ara, 66100, Chieti, Italy

    C. Colosimo

  2. Department of Radiology, The Ohio State University Hospitals, 657 Means Hall, 1654 Upham Drive, Columbus, Ohio, 43210-1228, USA

    M. V. Knopp

  3. Service de Neuroradiologie, Hôpital Pellegrin, Place Amélie Raba Léon, 33076, Bordeaux, France

    X. Barreau

  4. Service de Neuroradiologie, Hôpital Charles Nicolle, 1 rue de Germont, 76031, Rouen, France

    E. Gérardin

  5. Worldwide Medical Affairs, Bracco Imaging SpA, Via E. Folli 50, 20134, Milano, Italy

    M. A. Kirchin

  6. Altana Pharma, 389 rue du Pressoir, 77350, Le Mée-sur-Seine, France

    F. Guézénoc

  7. Bracco Altana Pharma GmbH, Max-Stromeyer-Strasse 116, 78467, Konstanz, Germany

    K. P. Lodemann

Authors
  1. C. Colosimo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. V. Knopp
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. X. Barreau
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Gérardin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. A. Kirchin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. Guézénoc
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K. P. Lodemann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. P. Lodemann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Colosimo, C., Knopp, M.V., Barreau, X. et al. A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours. Neuroradiology 46, 655–665 (2004). https://doi.org/10.1007/s00234-003-1128-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00234-003-1128-4

Key words

Search

Navigation